Pan-American League of Associations for Rheumatology (PANLAR) | September 17 - 20, 2020

Virtual Meeting

  • Integrated Safety Summary of the Novel, Intra-articular Agent Lorecivivint (SM04690), a CLK/DYRK1A Inhibitor That Modulates the Wnt Pathway, in Subjects with Knee Osteoarthritis

  • The Novel, Intra-articular CLK/DYRK1A Inhibitor Lorecivivint (LOR; SM04690), Which Modulates the Wnt Pathway, Improved Responder Outcomes in Subjects with Knee Osteoarthritis: A Post Hoc Analysis from a Phase 2b Trial

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases | August 20 - 22, 2020

Virtual Meeting

  • The Novel, Intra-articular CLK/DYRK1A Inhibitor Lorecivivint (LOR; SM04690), Which Modulates the Wnt Pathway, Improved Responder Outcomes in Subjects with Knee Osteoarthritis: A Post Hoc Analysis from a Phase 2b Trial

  • Safety Profile of the Novel, Intra-articular Agent Lorecivivint (LOR; SM04690), a CLK/DYRK1A Inhibitor That Modulates the Wnt Pathway, in Subjects with Knee Osteoarthritis

  • Lorecivivint (SM04690), an Intra-articular, Small-Molecule CLK/DYRK1A Inhibitor That Modulates the Wnt Pathway, as a Potential Treatment for Meniscal Injuries

  • Items Driving WOMAC Pain Subscore Changes Due to Lorecivivint, a Potential Disease-Modifying Treatment for Knee Osteoarthritis: A Post Hoc Analysis of Phase 2b Trial Data

  • Lorecivivint (SM04690), a Potential Disease-Modifying Treatment For Knee Osteoarthritis, Demonstrated Cartilage-Protective Effects on Human Osteoarthritic Explants

  • SM04755, a Potential Disease-Modifying Treatment for Tendinopathy, Modulates the Wnt Pathway via Inhibition of CLKs and DYRK1A

American Association for Cancer Research (AACR) Annual Meeting | June 22 - 24, 2020

Virtual Meeting

  • SM08502, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Antitumor Effects and Wnt Pathway Inhibition in Castration-Resistant Prostate Cancer (CRPC) Models

  • Transcriptome Analysis of TCGA Prostate Cancer Samples Identifies an Association of Poorer Survival and Aggressive Disease Biology with CDC-like Kinase (CLK) Expression and Spliceosome Regulation

  • SM08502, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Antitumor Effects and Wnt and Cyclin D-CDK4/6-RB Pathway Inhibition in Hormone-Receptor-Positive (HR+) Breast Cancer Models

European League Against Rheumatism (EULAR) | June 03 - 06, 2020

Virtual Meeting

  • Safety Profile of the Novel, Intra-articular Agent Lorecivivint (LOR; SM04690), a CLK/DYRK1A Inhibitor That Modulates the Wnt Pathway, in Subjects with Knee Osteoarthritis

  • The Novel, Intra-Articular CLK/DYRK1a Inhibitor Lorecivivint (LOR; SM04690), Which Modulates the Wnt Pathway, Improved Responder Outcomes in Subjects with Knee Osteoarthritis: A Post Hoc Analysis from a Phase 2b Trial

  • Items Driving WOMAC Pain Subscore Changes Due to Lorecivivint, a Potential Disease-Modifying Treatment for Knee Osteoarthritis: A Post Hoc Analysis of Phase 2b Trial Data

  • SM04755, a Potential Disease-Modifying Treatment for Tendinopathy, Modulates the Wnt Pathway via Inhibition of CLKs and DYRK1A

  • Lorecivivint (SM04690), an Intra-articular, Small-Molecule CLK/DYRK1A Inhibitor that Modulates the Wnt Pathway, as a Potential Treatment for Meniscal Injuries

  • Lorecivivint (SM04690), a Potential Disease-Modifying Treatment for Knee Osteoarthritis, Demonstrated Cartilage-Protective Effects on Human Osteoarthritic Explants

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) | May 18 - 20, 2020

Virtual Meeting

  • Lorecivivint, a Potential Disease-Modifying Treatment for Knee Osteoarthritis: Factors Driving WOMAC Pain Subscore Changes - A Post Hoc Analysis of Phase 2b Data

Advances in Alzheimer’s and Parkinson’s Disease Therapies (AD/PD) Focus Meeting 2020 | April 02 - 05, 2020

Virtual Meeting

  • SM07883, a Novel, Potent, and Selective Oral DYRK1A Inhibitor, Reduces Neuroinflammatory Responses in Mouse Models

European Workshop for Rheumatology Research (EWRR) | February 13 - 15, 2020

Leuven, Belgium

  • Lorecivivint (SM04690), a Potential Disease-Modifying Treatment for Knee Osteoarthritis, Demonstrated Cartilage-Protective Effects on Human Osteoarthritic Explants

Tau2020 Global Conference | February 12 - 13, 2020

Washington, D.C

  • SM07883, a Novel, Oral DYRK1A Kinase Inhibitor, Reduced Tau Pathology and Associated Behavioral Deficits in Preclinical Models

Orthopaedic Research Society (ORS) | February 08 - 11, 2020

Phoenix, AZ

  • SM04755, a Potential Disease-Modifying Treatment for Tendinopathy, Modulates the Wnt Pathway via Inhibition of CLK2 and DYRK1A

Award Winning